This is an accredited continuing education series of one (1) podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC/ACPE podcast will spotlight latest advances in the treatment of HF featuring a leading expert reporting from the 2024 ACC Conference.

Launch Date: April 11, 2024

Release Date: April 11, 2024

Expiration Date: March 31, 2025

FACULTY BIO

Peter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACC

Director of Preventive Cardiology

CGH Medical Center

Professor of Clinical Family and Community Medicine

University of Illinois School of Medicine

Adjunct Professor of Medicine

Division of Cardiology

Johns Hopkins University School of Medicine

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/acc-conference-coverage-clinical-clips-in-heart-failure-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Launch Date: February 16, 2024

Release Date: January 29, 2024

Expiration Date: January 31, 2025

FACULTY

R. Scott Wright, MD, FACC, FESC, FAHA

Professor of Medicine

Consultant in Cardiology

Mayo Clinic

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

Director

Mount Sinai Fuster Heart Hospital

Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Launch Date: February 16, 2024

Release Date: January 29, 2024

Expiration Date: January 31, 2025

FACULTY

R. Scott Wright, MD, FACC, FESC, FAHA

Professor of Medicine

Consultant in Cardiology

Mayo Clinic

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

Director

Mount Sinai Fuster Heart Hospital

Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025

FACULTY

R. Scott Wright, MD, FACC, FESC, FAHA

Professor of Medicine

Consultant in Cardiology

Mayo Clinic

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

Director

Mount Sinai Fuster Heart Hospital

Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link prior to listening to this episode.